Share Data

At Anavex Life Sciences, we strive to produce sustained strong performance and shareholder value.

NASDAQ: AVXL

Industry

Biopharmaceutical

Sector

New drug discovery

Fiscal year end

September 30

Shares issued and outstanding

82,112,511*

Stock purchase warrants

160,000 **

Stock options

14,109,363**

Fully diluted

96,355,874**

Cash

$143.8 million

Debt

Nil **

Trading symbol

AVXL

52-week range

$4.87 - $10.45

Financial statements and filings

Anavex's filings can be found on EDGAR

Investor relations

Transfer agent

Nevada Agency and Trust

50 West Liberty Street,

Suite 880

Reno, Nevada 89501

Fax: (775) 322-5623

Resident Agent

* As of Febuary 7, 2024

** As of December 31, 2023

Forms - Reverse Stock Split

Internal Revenue Service (United States) - Form 8937